Firefly Neuroscience (AIFF) Cash from Discontinued Operations (2022 - 2023)
Firefly Neuroscience (AIFF) posted Cash from Discontinued Operations of -$693106.0 for Q1 2023, down 117.32% on a QoQ basis from $4.0 million in Q4 2022, and up 2.09% year-over-year from -$678939.8 in Q1 2022.
Powered by 
Analysis
Firefly Neuroscience (AIFF) Cash from Discontinued Operations (2022 - 2023) Analysis & Trends
Firefly Neuroscience has reported Cash from Discontinued Operations for 2 years, with the latest figure at -$693106.0 in Q1 2023.
- On a quarterly basis, Cash from Discontinued Operations rose 2.09% year-over-year to -$693106.0 in Q1 2023; TTM through Dec 2023 was -$693106.0, a 141.49% decrease from a year earlier, with the FY2023 full-year figure at -$693106.0, down 141.49% from the prior year.
- Cash from Discontinued Operations was -$693106.0 for Q1 2023 at Firefly Neuroscience, down from $4.0 million in the prior quarter.
- The five-year high for Cash from Discontinued Operations was $4.0 million in Q4 2022, with the low at -$1.0 million in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 31.10 Bn | 29.22 Bn | 2.18 Bn | - |
| 2 | Lantheus Holdings | 6.59 Bn | 6.00 Bn | 241.86 Mn | - |
| 3 | Heartflow | 4.24 Bn | 3.87 Bn | 53.19 Mn | - |
| 4 | Neogen | 2.58 Bn | 2.39 Bn | 107.80 Mn | - |
| 5 | Butterfly Network | 1.75 Bn | 1.62 Bn | 23.29 Mn | - |
| 6 | QuidelOrtho | 954.15 Mn | 830.75 Mn | - | - |
| 7 | Ceribell | 944.88 Mn | 815.62 Mn | 25.94 Mn | - |
| 8 | Anbio Biotechnology | 941.05 Mn | 929.15 Mn | - | - |
| 9 | Varex Imaging | 780.16 Mn | 694.86 Mn | 76.70 Mn | - |
| 10 | Firefly Neuroscience | 23.25 Mn | 14.03 Mn | 253,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | -693,106.00 |
| Dec 31, 2022 | 4.00 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -588,993.00 |
| Mar 31, 2022 | -707,876.00 |